Cargando…

Cytomegalovirus DNAemia Requiring (Val)Ganciclovir Treatment for More Than 8 Weeks Is a Key Factor in the Development of Antiviral Drug Resistance

BACKGROUND: Prolonged (val)ganciclovir [(V)GCV] exposure for ≥6 weeks is a known predisposing factor for cytomegalovirus (CMV) drug resistance. However, the selection of this threshold was based on limited data. In this study, we sought to reappraise the risk factors for the development of (V)GCV re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Acquier, M, Taton, B, Alain, S, Garrigue, I, Mary, J, Pfirmann, P, Visentin, J, Hantz, S, Merville, P, Kaminski, H, Couzi, L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933945/ https://www.ncbi.nlm.nih.gov/pubmed/36817745 http://dx.doi.org/10.1093/ofid/ofad018

Ejemplares similares

Development and Dynamics of Cytomegalovirus UL97 Ganciclovir Resistance Mutations in Transplant Recipients Detected by Next-Generation Sequencing
por: Lodding, Isabelle P, et al.
Publicado: (2021)

Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients
por: Khurana, Mark P, et al.
Publicado: (2019)

Genomic Markers Associated with Cytomegalovirus DNAemia in Kidney Transplant Recipients
por: Shapira, Guy, et al.
Publicado: (2023)

Analysis of Ganciclovir-Resistant Cytomegalovirus Infection Caused by the UL97 Gene Mutation in Codons 460 and 520 in Pediatric Patients: A Case Series
por: Boonsathorn, Sophida, et al.
Publicado: (2019)

1750. Epidemiology of Cytomegalovirus DNAemia in Pediatric Solid-Organ Transplant Patients
por: Valencia Deray, Kristen, et al.
Publicado: (2019)

Direct and Indirect Effects of Cytomegalovirus-Induced γδ T Cells after Kidney Transplantation
por: Couzi, Lionel, et al.
Publicado: (2015)

Ganciclovir/letermovir: Rebound Cytomegalovirus hepatitis, acquired resistance to ganciclovir and nephrotoxicity: case report
Publicado: (2020)

The human cytomegalovirus terminase complex as an antiviral target: a close-up view
por: Ligat, G, et al.
Publicado: (2018)

Association between Antiviral Prophylaxis and Cytomegalovirus and Epstein–Barr Virus DNAemia in Pediatric Recipients of Allogeneic Hematopoietic Stem Cell Transplant
por: Diop, Ndeye Soukeyna, et al.
Publicado: (2021)

Ganciclovir-resistant cytomegalovirus infection in renal transplantation
por: Vaz, Raquel, et al.
Publicado: (2014)

1597. Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus (CMV) Infection and Disease in Solid Organ Transplant (SOT) Recipients
por: Khurana, Mark Poulsen, et al.
Publicado: (2018)

Presumed neonatal cytomegalovirus retinitis treated with intravenous ganciclovir
por: Suganya, A, et al.
Publicado: (2020)

Preemptive ganciclovir for mechanically ventilated patients with cytomegalovirus reactivation
por: Papazian, Laurent, et al.
Publicado: (2021)

The risk of early and late cytomegalovirus DNAemia associated with Campath use in stem cell transplant recipients
por: Buyck, Hubertus C, et al.
Publicado: (2009)

Evaluation of risk factors for cytomegalovirus DNAemia after end of regular prophylaxis after heart transplantation
por: Immohr, Moritz Benjamin, et al.
Publicado: (2023)

Treatment outcomes of reduced-dose intravitreal ganciclovir for cytomegalovirus retinitis
por: Choopong, Pitipol, et al.
Publicado: (2016)

Ganciclovir penetrates into the cerebrospinal fluid of an infant with congenital cytomegalovirus infection
por: Natale, Fabio, et al.
Publicado: (2015)

2104. Cytomegalovirus DNAemia Patterns in Mismatched Solid Organ Transplant Recipients: A Retrospective Cohort Study.
por: Garcia, Oscar A Fernandez, et al.
Publicado: (2022)

Efficacy and safety of topical ganciclovir in the management of cytomegalovirus (CMV)-related anterior uveitis
por: Wong, John X. H., et al.
Publicado: (2016)

Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation
por: Lodding, I P, et al.
Publicado: (2018)

Outcome of Cytomegalovirus Colitis in Inflammatory Bowel Disease with Different Regimes of Ganciclovir
por: Ahmed, Iftikhar, et al.
Publicado: (2018)

Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads
por: Märtson, Anne-Grete, et al.
Publicado: (2021)

A Patient with Lymphadenopathy, Hypercalcemia, and Kidney Injury
por: Chauveau, Bertrand, et al.
Publicado: (2023)

Unexpectedly High Prevalence of Cytomegalovirus DNAemia in Older Children and Adolescents With Perinatally Acquired Human Immunodeficiency Virus Infection
por: Yindom, Louis-Marie, et al.
Publicado: (2019)

Combined Therapy with Intravenous Immunoglobulins, Letermovir and (Val-)Ganciclovir in Complicated Courses of CMV-Infection in Transplant Recipients
por: Di Cristanziano, Veronica, et al.
Publicado: (2021)

Safety of Valganciclovir 450 mg 3 Times Weekly for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients Requiring Hemodialysis
por: Ecabert, Danielle, et al.
Publicado: (2021)

Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation
por: Ding, Zhaoqing, et al.
Publicado: (2014)

The antiviral drug ganciclovir does not inhibit microglial proliferation and activation
por: Skripuletz, Thomas, et al.
Publicado: (2015)

Dexamethasone inhibits the HSV-tk/ ganciclovir bystander effect in malignant glioma cells
por: Robe, Pierre A, et al.
Publicado: (2005)

The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein
por: Shannon-Lowe, Claire D, et al.
Publicado: (2010)

Successful Treatment with Ganciclovir for Cytomegalovirus Duodenitis following Allogenic Bone Marrow Transplantation
por: Ahn, Jin Hee, et al.
Publicado: (1999)

Cytomegalovirus-associated esophageal ulcer in an immunocompetent infant: When should ganciclovir be administered?
por: Jang, Hyo-Jeong, et al.
Publicado: (2012)

Therapeutic Drug Monitoring of Ganciclovir Treatment for Cytomegalovirus Infections Among Immunocompromised Children
por: Stockmann, Chris, et al.
Publicado: (2016)

Predictor of Liver Biochemistry Improvement in Patients with Cytomegalovirus Cholestasis after Ganciclovir Treatment
por: Puspita, Gina, et al.
Publicado: (2022)

Ganciclovir Antiviral Therapy in Advanced Idiopathic Pulmonary Fibrosis: An Open Pilot Study
por: Egan, J. J., et al.
Publicado: (2011)

Emerging (val)ganciclovir resistance during treatment of congenital CMV infection: a case report and review of the literature
por: Morillo-Gutierrez, Beatriz, et al.
Publicado: (2017)

Cytomegalovirus Cell-Mediated Immunity: Ready for Routine Use?
por: Bestard, Oriol, et al.
Publicado: (2023)

An Alternative Approach to Isoganciclovir: A Prominent Impurity in the Antiviral Drug Ganciclovir
por: Sundaram, Dhanraj T. S. S., et al.
Publicado: (2015)

Cytomegalovirus Retinitis in an ALL Child during Maintenance Therapy Treated Successfully with Intravenous Ganciclovir
por: Celiker, Hande, et al.
Publicado: (2014)

Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis
por: Vaziri, Siavash, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_o82scnu0buo24mnvst2sbtpja0